Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

$11.22 -0.22 (-1.92%)

High $11.49	Low $11.20	Trades 4,718	Turnover $7,499,551	Volume 664,557
30 June 2023 at 4:12pm

Market Cap (15-Sep) $6,013,292,544 (204th)	Close (30-Jun) $11.22 0 (0%)	Volume (30-Jun) 664,557	Shortsold (10-Sep) 36,494,764 (10.74%) (11th)
52w High $18.32	52w Low $8.26	P/E 156.25	EPS 0.14
ASX Announcements (7d) -	Twitter Mentions (7d) 0+	AFR Articles (7d) -	News Articles (7d) 2+

Short Interest

ASIC data, 10 Sep 2026

% Shorted

10.74% 0.17

vs 10.58% prior report

Most Shorted Rank

11th

of 692 shorted ASX stocks

Peak Short

16.51%

Apr 2026

Days to Cover

20.9

at 50d avg vol

View full short position history →

	Subject
	TLX TLX Ann: 2022 Interim Report
	1 (current) 2 3
	TLX TLX Ann: Appendix 4D - Results for announcement to the market
	TLX TLX Ann: Grand Pharmaceutical Group's investment in Telix
	TLX TLX Article: China’s Grand Decade drops $73m Telix stake, JPM seeks buyers
	TLX TLX Ann: Telix 1H 2022 Financial Results Investor Call Notification
	TLX TLX Article: Fund managers back market darling Telix Pharmaceuticals
	TLX TLX Ann: APAC Regulatory Progress Prostate and Kidney Cancer Imaging
	TLX TLX Ann: Appendix 4C and Activities Report for June 2022 Quarter
	TLX TLX Ann: Kevin Richardson appointed as CEO, Telix Americas
	TLX TLX Ann: Zircon Kidney Cancer Imaging Study completes Enrollment
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Distribution Agreement with Isologic for Illuccix in Canada
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001
	TLX TLX Ann: Notification regarding unquoted securities - TLX
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Notification of cessation of securities - TLX
	TLX TLX Ann: Expansion of Partnership with RefleXion for Prostate Cancer
	TLX TLX Ann: Presentation to Jefferies Global Healthcare Conference
	TLX TLX Ann: Telix receives AUD$17.25 million R&D tax refund
	TLX TLX Ann: App 3Y Change in Director interests - T Olson
	TLX TLX Ann: Leadership changes including Darren Smith appointment as CFO
	TLX TLX Ann: Illuccix Reimbursement Milestone and Launch Updates
	TLX TLX Ann: Notification regarding unquoted securities - TLX
	TLX TLX Ann: App 3Y - Change in Directors Interests - C Behrenbruch
	TLX TLX Ann: App 3Y - Change in Directors Interests - T Olson
	TLX TLX Ann: App 3Z - Final Directors Interests Notice - O Buck
	TLX TLX Ann: Results of 2022 Annual General Meeting
	TLX TLX Ann: CEO's Address to AGM
	TLX TLX Ann: Chairman's Address to Annual General Meeting
	TLX TLX Ann: AGM - change to proposed amendments to Telix Constitution
	TLX TLX Ann: Appendix 3Y - Change in Directors Interests - O Buck
	TLX TLX Ann: Appendix 4C and Activities Report for March 2022 quarter
	TLX TLX Ann: Securities Dealing Policy - adopted 11 April 2022
	TLX TLX Ann: 2022 AGM Notice of Meeting, Proxy Form and Online Guide
	TLX TLX Ann: ProstACT TARGET Phase II Study Ethics Approval
	TLX TLX Ann: Telix Enters Licence Agreement with Lilly for Olaratumab
	TLX TLX Ann: Notification regarding unquoted securities - TLX
	TLX TLX Ann: Telix, GMS & Monash Awarded $23 million Federal Funding
	TLX TLX Ann: Commercial Launch - Illuccix Now Available to Order in US
	TLX TLX Ann: Appendix 3X - Initial Directors Interest Notice
	TLX TLX Ann: Change of Composition of the Telix Board of Directors
	TLX TLX Ann: FDA Orphan Drug Designation for Bone Marrow Conditioning
	TLX TLX Ann: Telix and Xiel Sign U.K. and Ireland Distribution Agreement
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Development of Glioblastoma Therapy Program
	TLX TLX Ann: Radiopharmaceutical Production Facility Buildout Commences
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Notice Required Under ASX Listing Rule 3.13.1

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

End of Day Prices

Date	Close	Volume	Change
15-Sep	$17.75	6,075,869	+1.41 (8.63%)
14-Sep	$16.34	4,719,870	+0.67 (4.28%)
11-Sep	$15.67	2,185,506	-1.09 (6.50%)
10-Sep	$16.76	1,751,436	+0.07 (0.42%)
09-Sep	$16.69	1,109,874	+0.19 (1.15%)
08-Sep	$16.50	1,119,678	+0.25 (1.54%)
07-Sep	$16.25	1,041,831	-0.22 (1.34%)
04-Sep	$16.47	1,525,374	+0.21 (1.29%)
03-Sep	$16.26	2,055,126	+0.57 (3.63%)
02-Sep	$15.69	1,564,041	+0.42 (2.75%)
01-Sep	$15.27	1,635,463	-0.09 (0.59%)
31-Aug	$15.36	1,047,148	-0.29 (1.85%)
28-Aug	$15.65	985,671	+0.07 (0.45%)
27-Aug	$15.58	1,267,960	+0.09 (0.58%)
26-Aug	$15.49	1,480,871	-0.67 (4.15%)
10 up, 5 down, and 0 flat days

Telix Pharmaceuticals Health Care Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom